Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.

Queralt Salas M, Prem S, Atenafu EG, Datt Law A, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A.

Bone Marrow Transplant. 2020 Feb 5. doi: 10.1038/s41409-020-0813-9. [Epub ahead of print]

PMID:
32024990
2.

Simultaneous versus sequential retroperitoneal, thoracic and cervical resection of post chemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.

Nason GJ, Donahoe L, de Perrot M, Aditya I, Jewett M, Bedard PL, Hansen AR, Chung P, Warde P, Anson-Cartwright L, Sweet J, O'Malley M, Atenafu EG, Hamilton RJ.

Urology. 2020 Jan 28. pii: S0090-4295(20)30082-0. doi: 10.1016/j.urology.2019.12.032. [Epub ahead of print]

PMID:
32004556
3.

Psychosocial screening and mental health in pediatric cancer: A randomized controlled trial.

Barrera M, Alexander S, Atenafu EG, Chung J, Hancock K, Solomon A, Desjardins L, Shama W, Mills D.

Health Psychol. 2020 Jan 23. doi: 10.1037/hea0000825. [Epub ahead of print]

PMID:
31971403
4.

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.

Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, McNamara C, Murphy T, Shuh AC, Yee K, Sibai H, Minden MD, Wei C, Stockley T, Kamel-Reid S, Schimmer AD.

Haematologica. 2020 Jan 2. pii: haematol.2019.235721. doi: 10.3324/haematol.2019.235721. [Epub ahead of print]

5.

Clinical outcomes and transfusion management following intracranial hemorrhage in patients with acute leukemia.

Nixon S, Lieberman L, Atenafu EG, Doherty M, Murray C, Wolfe A, Brandys D, Rowland S, Kwan BY, Yu E, Lechner B, Maze D.

Transfusion. 2020 Feb;60(2):269-274. doi: 10.1111/trf.15621. Epub 2019 Dec 6.

PMID:
31808560
6.

Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.

Rastgoo N, Wu J, Liu M, Pourabdollah M, Atenafu EG, Reece D, Chen W, Chang H.

Haematologica. 2019 Nov 28. pii: haematol.2019.227579. doi: 10.3324/haematol.2019.227579. [Epub ahead of print]

7.

Prognostic relevance of CD123 expression in adult AML with normal karyotype.

Jiang G, Atenafu EG, Capo-Chichi JM, Minden MD, Chang H.

Br J Haematol. 2020 Jan;188(1):181-184. doi: 10.1111/bjh.16307. Epub 2019 Nov 23. No abstract available.

PMID:
31758553
8.

Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival.

Prem S, Atenafu EG, Lam W, Law A, Michelis FV, Kim D, Viswabandya A, Howard Lipton J, Mattsson J, Kumar R.

Eur J Haematol. 2020 Feb;104(2):116-124. doi: 10.1111/ejh.13353. Epub 2019 Dec 2.

PMID:
31737967
9.

Universal venous thromboembolism policy is effective but may not adequately protect hospitalized cancer patients with larger BMI.

Xu A, Sibai H, Atenafu EG, Japs K, Seki JT.

J Thromb Thrombolysis. 2020 Jan;49(1):113-120. doi: 10.1007/s11239-019-01975-x.

PMID:
31677148
10.

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras.

Li AY, Atenafu EG, Bernard RS, Masih-Khan E, Reece D, Franke N, Tiedemann R, Prica A, Trudel S, Kukreti V, Chen CI.

Bone Marrow Transplant. 2019 Sep 26. doi: 10.1038/s41409-019-0697-8. [Epub ahead of print]

PMID:
31558786
11.

Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation.

Salas MQ, Atenafu EG, Bautista MR, Prem S, Lam W, Datt Law A, Shaibani ZA, Kim DDH, Michelis FV, Lipton JH, Viswabandya A, Mattsson J, Kumar R.

Eur J Haematol. 2020 Jan;104(1):36-45. doi: 10.1111/ejh.13332. Epub 2019 Oct 6.

PMID:
31549435
12.

Postoperative Stereotactic Body Radiotherapy for Spinal Metastases and the Impact of Epidural Disease Grade.

Alghamdi M, Sahgal A, Soliman H, Myrehaug S, Yang VXD, Das S, Wilson J, Campbell M, Lee YK, Cawricz M, Da Costa L, Atenafu EG, Tseng CL.

Neurosurgery. 2019 Dec 1;85(6):E1111-E1118. doi: 10.1093/neuros/nyz349.

PMID:
31506671
13.

Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia.

Salas MQ, Prem S, Atenafu EG, Law AD, Lam W, Al-Shaibani Z, Loach D, Kim DDH, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A.

Eur J Haematol. 2019 Nov;103(5):510-518. doi: 10.1111/ejh.13321. Epub 2019 Sep 9.

PMID:
31449699
14.

Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment.

Prem S, Atenafu EG, Avena J, Bautista R, Law A, Lam W, Michelis FV, Kim DDH, Viswabandya A, Lipton JH, Mattsson J, Kumar R.

Eur J Haematol. 2019 Nov;103(5):483-490. doi: 10.1111/ejh.13314. Epub 2019 Sep 5.

PMID:
31418930
15.

Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases.

Nguyen TK, Sahgal A, Detsky J, Atenafu EG, Myrehaug S, Tseng CL, Husain Z, Heyn C, Maralani P, Ruschin M, Perry J, Soliman H.

Neuro Oncol. 2020 Jan 11;22(1):84-93. doi: 10.1093/neuonc/noz144.

PMID:
31412120
16.

Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases.

Soliman H, Myrehaug S, Tseng CL, Ruschin M, Hashmi A, Mainprize T, Spears J, Das S, Yang V, da Costa L, Maralani P, Heyn C, Atenafu EG, Sahgal A.

Neurosurgery. 2019 Nov 1;85(5):E860-E869. doi: 10.1093/neuros/nyz162.

PMID:
31173150
17.

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.

Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM.

Ann Oncol. 2019 Aug 1;30(8):1370-1380. doi: 10.1093/annonc/mdz176.

PMID:
31150059
18.

Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants.

Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, Michelis FV, Thyagu S, Kim DDH, Howard Lipton J, Kumar R, Viswabandya A.

Eur J Haematol. 2019 Jun;102(6):486-493. doi: 10.1111/ejh.13230. Epub 2019 Apr 29.

PMID:
30924973
19.

Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.

Hamilton RJ, Nayan M, Anson-Cartwright L, Atenafu EG, Bedard PL, Hansen A, Chung P, Warde P, Sweet J, O'Malley M, Sturgeon J, Jewett MAS.

J Clin Oncol. 2019 Aug 1;37(22):1919-1926. doi: 10.1200/JCO.18.01250. Epub 2019 Feb 25.

PMID:
30802156
20.

Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.

Alahmadi M, Masih-Khan E, Atenafu EG, Chen C, Kukreti V, Tiedemann R, Trudel S, Reece DE.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):e195-e203. doi: 10.1016/j.clml.2018.12.007. Epub 2018 Dec 20.

PMID:
30723035
21.

Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.

Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G.

HPB (Oxford). 2019 Jun;21(6):731-738. doi: 10.1016/j.hpb.2018.10.005. Epub 2018 Nov 1.

PMID:
30391218
22.

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.

Brandwein JM, Seki JT, Atenafu EG, Rostom A, Lutynski A, Rydlewski A, Schimmer AD, Schuh AC, Gupta V, Yee KWL.

Support Care Cancer. 2019 Jun;27(6):2295-2300. doi: 10.1007/s00520-018-4515-4. Epub 2018 Oct 19.

PMID:
30341536
23.

Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose.

Moraes FY, Winter J, Atenafu EG, Dasgupta A, Raziee H, Coolens C, Millar BA, Laperriere N, Patel M, Bernstein M, Kongkham P, Zadeh G, Conrad T, Chung C, Berlin A, Shultz DB.

Neuro Oncol. 2019 Feb 14;21(2):242-251. doi: 10.1093/neuonc/noy159.

24.

Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis.

Prince RM, Powis M, Zer A, Atenafu EG, Krzyzanowska MK.

Eur J Cancer Care (Engl). 2019 Jan;28(1):e12909. doi: 10.1111/ecc.12909. Epub 2018 Sep 20.

PMID:
30238542
25.

Seizure Identification by Critical Care Providers Using Quantitative Electroencephalography.

Lalgudi Ganesan S, Stewart CP, Atenafu EG, Sharma R, Guerguerian AM, Hutchison JS, Hahn CD.

Crit Care Med. 2018 Dec;46(12):e1105-e1111. doi: 10.1097/CCM.0000000000003385.

PMID:
30188384
26.

Stereotactic Body Radiotherapy for Spinal Metastases at the Extreme Ends of the Spine: Imaging-Based Outcomes for Cervical and Sacral Metastases.

Zeng KL, Myrehaug S, Soliman H, Tseng CL, Atenafu EG, Campbell M, Faruqi S, Lee YK, Ruschin M, da Costa L, Yang V, Spears J, Heyn C, Maralani PJ, Whyne C, Yee A, Sahgal A.

Neurosurgery. 2019 Nov 1;85(5):605-612. doi: 10.1093/neuros/nyy393.

PMID:
30169694
27.

Predicting Escalated Care in Infants With Bronchiolitis.

Freire G, Kuppermann N, Zemek R, Plint AC, Babl FE, Dalziel SR, Freedman SB, Atenafu EG, Stephens D, Steele DW, Fernandes RM, Florin TA, Kharbanda A, Lyttle MD, Johnson DW, Schnadower D, Macias CG, Benito J, Schuh S; Pediatric Emergency Research Networks (PERN).

Pediatrics. 2018 Sep;142(3). pii: e20174253. doi: 10.1542/peds.2017-4253. Epub 2018 Aug 20. Erratum in: Pediatrics. 2019 Feb;143(2):.

28.

Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.

Nicholas MN, Khoja L, Atenafu EG, Hogg D, Quirt I, Butler M, Joshua AM.

Melanoma Res. 2018 Dec;28(6):571-577. doi: 10.1097/CMR.0000000000000468.

PMID:
30067547
29.

Imaging-Based Outcomes for 24 Gy in 2 Daily Fractions for Patients with de Novo Spinal Metastases Treated With Spine Stereotactic Body Radiation Therapy (SBRT).

Tseng CL, Soliman H, Myrehaug S, Lee YK, Ruschin M, Atenafu EG, Campbell M, Maralani P, Yang V, Yee A, Sahgal A.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):499-507. doi: 10.1016/j.ijrobp.2018.06.047. Epub 2018 Jul 10.

30.

Stereotactic radiosurgery for resected brain metastasis: Cavity dynamics and factors affecting its evolution.

Alghamdi M, Hasan Y, Ruschin M, Atenafu EG, Myrehaug S, Tseng CL, Spears J, Mainprize T, Sahgal A, Soliman H.

J Radiosurg SBRT. 2018;5(3):191-200.

31.

Hypoxia Detection in Infiltrative Astrocytoma: Ferumoxytol-based Quantitative BOLD MRI with Intraoperative and Histologic Validation.

Maralani PJ, Das S, Mainprize T, Phan N, Bharatha A, Keith J, Munoz DG, Sahgal A, Symons S, Ironside S, Faraji-Dana Z, Eilaghi A, Chan A, Alcaide-Leon P, Shearkhani O, Jakubovic R, Atenafu EG, Zaharchuk G, Mikulis D.

Radiology. 2018 Sep;288(3):821-829. doi: 10.1148/radiol.2018172601. Epub 2018 Jun 26.

PMID:
29944077
32.

Impact of Magnetic Resonance Imaging on Gross Tumor Volume Delineation in Non-spine Bony Metastasis Treated With Stereotactic Body Radiation Therapy.

Raman S, Chin L, Erler D, Atenafu EG, Cheung P, Chu W, Chung H, Loblaw A, Poon I, Rubenstein J, Soliman H, Sahgal A, Tseng CL.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):735-743.e1. doi: 10.1016/j.ijrobp.2018.03.010. Epub 2018 Mar 17.

PMID:
29748100
33.

Laboratory reference intervals in the assessment of iron status in young children.

Parkin PC, Hamid J, Borkhoff CM, Abdullah K, Atenafu EG, Birken CS, Maguire JL, Azad A, Higgins V, Adeli K.

BMJ Paediatr Open. 2017 Aug 31;1(1):e000074. doi: 10.1136/bmjpo-2017-000074. eCollection 2017.

34.

A randomized controlled trial of a group intervention for siblings of children with cancer: Changes in symptoms of anxiety in siblings and caregivers.

Barrera M, Atenafu EG, Schulte F, Nathan PC, Hancock K, Saleh A.

Psychooncology. 2018 Jun;27(6):1629-1634. doi: 10.1002/pon.4707. Epub 2018 Apr 16.

PMID:
29573047
35.

A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.

Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ.

Eur Urol Focus. 2018 Dec;4(6):995-1001. doi: 10.1016/j.euf.2018.01.015. Epub 2018 Feb 7.

PMID:
29428550
36.

Evaluation of the Efficacy of Rotational Corrections for Standard-Fractionation Head and Neck Image-Guided Radiotherapy.

Kung JS, Tran WT, Poon I, Atenafu EG, Courneyea L, Higgins K, Enepekides D, Sahgal A, Chin L, Karam I.

Technol Cancer Res Treat. 2018 Jan-Dec;18:1533033819853824. doi: 10.1177/1533033819853824.

37.

Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation.

Deotare U, Atenafu EG, Loach D, Michelis FV, Kim DD, Thyagu S, Lipton JH, Messner HA, Viswabandya A.

Bone Marrow Transplant. 2018 Mar;53(3):361-365. doi: 10.1038/s41409-017-0053-9. Epub 2017 Dec 21. No abstract available.

PMID:
29269806
38.

Serial 4DCT/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy.

Bissonnette JP, Yap ML, Clarke K, Shessel A, Higgins J, Vines D, Atenafu EG, Becker N, Leavens C, Bezjak A, Jaffray DA, Sun A.

Radiother Oncol. 2018 Feb;126(2):347-354. doi: 10.1016/j.radonc.2017.11.023. Epub 2017 Dec 12.

PMID:
29246584
39.

Association of wheeze with lung function decline in children with sickle cell disease.

Bendiak GN, Mateos-Corral D, Sallam A, Atenafu EG, Kirby M, Odame I, Bikangaga P, Subbarao P, Grasemann H.

Eur Respir J. 2017 Nov 30;50(5). pii: 1602433. doi: 10.1183/13993003.02433-2016. Print 2017 Nov. No abstract available.

40.

Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.

Khalil MMI, Lipton JH, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Viswabandya A, Messner HA, Michelis FV.

Eur J Haematol. 2018 Feb;100(2):198-205. doi: 10.1111/ejh.13000. Epub 2017 Dec 13.

PMID:
29168234
41.

Dosimetric feasibility of the hybrid Magnetic Resonance Imaging (MRI)-linac System (MRL) for brain metastases: The impact of the magnetic field.

Tseng CL, Eppinga W, Seravalli E, Hackett S, Brand E, Ruschin M, Lee YK, Atenafu EG, Sahgal A.

Radiother Oncol. 2017 Nov;125(2):273-279. doi: 10.1016/j.radonc.2017.09.036. Epub 2017 Oct 24.

PMID:
29079310
42.

Chemical Stability of Plerixafor after Opening of Single-Use Vial.

Seki JT, Bozovic A, Lee R, Kwong R, Atenafu EG, Xu A, Huh JH.

Can J Hosp Pharm. 2017 Jul-Aug;70(4):270-275. Epub 2017 Aug 31.

43.

Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.

Chen Y, Pourabdollah M, Atenafu EG, Tierens A, Schimmer A, Chang H.

Leuk Res. 2017 Oct;61:39-43. doi: 10.1016/j.leukres.2017.08.011. Epub 2017 Aug 25.

PMID:
28886412
44.

Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.

Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):870-878.e1. doi: 10.1016/j.clml.2017.07.006. Epub 2017 Jul 15.

PMID:
28803825
45.

Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.

Sun HL, Atenafu EG, Tsang R, Kukreti V, Marras TK, Crump M, Kuruvilla J.

Leuk Lymphoma. 2017 Nov;58(11):2607-2614. doi: 10.1080/10428194.2017.1307980. Epub 2017 May 15.

PMID:
28504035
46.

Determinants of social competence in pediatric brain tumor survivors who participated in an intervention study.

Barrera M, Atenafu EG, Schulte F, Bartels U, Sung L, Janzen L, Chung J, Cataudella D, Hancock K, Saleh A, Strother D, McConnell D, Downie A, Hukin J, Zelcer S.

Support Care Cancer. 2017 Sep;25(9):2891-2898. doi: 10.1007/s00520-017-3708-6. Epub 2017 Apr 14.

PMID:
28411324
47.

Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia.

Khoral P, Atenafu EG, Craddock KJ, Schimmer A, Chang H.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):215-219. doi: 10.1016/j.clml.2017.02.009. Epub 2017 Feb 17.

PMID:
28395813
48.

Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.

Mason M, Maurice C, McNamara MG, Tieu MT, Lwin Z, Millar BA, Menard C, Laperriere N, Milosevic M, Atenafu EG, Mason W, Chung C.

J Neurooncol. 2017 May;132(3):463-471. doi: 10.1007/s11060-017-2395-y. Epub 2017 Mar 22.

PMID:
28332000
49.

Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.

Guo RJ, Atenafu EG, Schimmer AD, Minden MD, Chang H.

Int J Lab Hematol. 2017 Aug;39(4):429-437. doi: 10.1111/ijlh.12649. Epub 2017 Mar 20.

PMID:
28318150
50.

Determinants of quality of life outcomes for survivors of pediatric brain tumors.

Barrera M, Atenafu EG, Schulte F, Bartels U, Sung L, Janzen L, Chung J, Cataudella D, Hancock K, Saleh A, Strother D, McConnell D, Downie A, Hukin J, Zelcer S.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26481. Epub 2017 Mar 10.

PMID:
28296130

Supplemental Content

Loading ...
Support Center